Floatz logo

Cyclophosphamide

Bispecific Antibody

Li ZhimingSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Bispecific Antibody cohort.

Asset / SponsorPhaseRating
Elranatamab
Pfizer
Phase 2B
Mezigdomide
Pfizer
Phase 2B
DEXAMETHASONE
Pfizer
Phase 2B
Benadryl
Pfizer
Phase 2B
Glofitamab
Li Zhiming
Phase 2CCC

View all 11 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →